{"entity":{"id":"lamassu-biotech","kind":"company","name":"Lamassu Biotech","aka":["Lamassu Bio Inc"],"tldr":"Lamassu Biotech is testing a tablet that switches back on p53, a protein that normally stops cancer growth, in tumours where p53 itself is still intact.","summary":"Lamassu Biotech is a private clinical-stage company that announced corporate offices in Cleveland in May 2024 and develops small molecules for oncology and metabolic indications, including a treatment for acute pancreatitis and a veterinary arm, Lamassu Pets. SA53 (SA53-OS) is an oral MDM2 inhibitor designed to reactivate wild-type p53, in a first-in-human phase 1/2a study (LB-SA53-101) in locally advanced or metastatic solid tumours (NCT06578624); initial safety and pharmacokinetic data were presented at ESMO 2026. Its first registered cancer trial, NCT06578624, was posted on ClinicalTrials.gov in August 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.lamassubiotech.com/"},{"label":"ESMO 2026 SA53 data release","url":"https://www.lamassubiotech.com/2026/10/26/lamassu-biotech-presents-initial-safety-and-pharmacokinetic-data-for-mdm2-inhibitor-sa53-from-first-in-human-phase-1-2a-study-at-esmo-congress-2026/"},{"label":"News releases","url":"https://www.lamassubiotech.com/news-releases/"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["mdm2-inhibitors"],"targets":["mdm2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06578624"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website and October 2026 release read on 29 October 2026. Founding year not stated on the pages read. The Cleveland location rests on the May 2024 release title about new corporate offices. The company website announces NIH grants; no equity round was read."],"hq":"Cleveland, OH","country":"US","companyType":"biotech","website":"https://www.lamassubiotech.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/lamassu-biotech/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"mdm2-inhibitors","kind":"technology","name":"MDM2 inhibitors","route":"/technologies/mdm2-inhibitors/"}],"target":[{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/"}],"trial":[{"id":"nct06578624","kind":"trial","name":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06578624/"}]}}